Diplomate American Board of Internal Medicine
Pulmonary & Sleep Associates - 785-234-5480 fax 785-234-3124
Veritas Clinical Specialties, Ltd. – 785-354-0735 fax 785-354-0736
WORK EXPERIENCE Current Employment: August 2004 – Present Attending Physician
Pulmonary & Sleep Associates Clinical Research Investigator Veritas Clinical Specialties, Ltd. 515 SW Horne Suite 200 Topeka, KS 66606
EDUCATION & TRAINING Fellowship 2001-2004
Pulmonary & Critical Care Fellowship Baylor College of Medicine Houston, TX Including experience in:
• Long Term Acute Care • Post-op Cardiovascular Care @ Texas Heart Institute • Adult Cystic Fibrosis Center • Baylor Lung Transplant Center • Sleep Medicine • Adult Asthma Clinic Residency 1998-2001
Internal Medicine Residency University of Tennessee Health Sciences Center Memphis, TN
Authorization Signature __________________________
• General Surgery – 6 months • Internal Medicine – 6 months
Medical School 1991-1996
Bachelor of Medicine (MB) Bachelor of Surgery (BS) The Aga Khan University, Pakistan
Undergraduate 1991
University of Cambridge “Advanced” level Certificate
University of Cambridge “Ordinary” level Certificate
BOARDS & CERTIFICATION Licensure: State of Kansas, Medical Doctor (MD) 04-30492 2005 American Board of Sleep Medicine 2004
Critical Care Medicine Board - Certified
Diplomate American Board of Internal Medicine
“Golden Apple” Award for Best Resident Teacher,
PMDC (Pakistan Medical and Dental Council) registration.
PROFESSIONAL MEMBERSHIPS 2002-03
Resident representative to Texas Medical Association.
RESEARCH EXPERIENCE
Sub-Investigator: Protocol 100013: “ A 12-Week, Double-Blind, Placebo-Controlled, Twice Daily Dosing Study to Assess the Efficacy and Safety of Ropinirole in Patients Suffering from Restless Legs Syndrome (RLS) Requiring Extended Treatment Coverage” GlaxoSmithKline October 2004-present Sub-Investigator: Protocol 100310: “A 12-Week, Double-Blind, Placebo-Controlled Study to Assess the Tolerability, Efficacy and Safety of Ropinirole Dosed PRN in Subjects with Restless Legs Syndrome (RLS) Who Respond to Open-Label Treatment with Ropinirole (TREAT RLS PRN)”
October 2004-present Sub-Investigator: Protocol HMR 3647A 4019: A Randomized, Double-Blind, Parallel-Group, Multicenter Study to Compare Clinical Health Outcomes of Telithromycinn versus Azithromycin in Outpatients with Community-Acquired Lower Respiratory Tract Infections (KEYS)
November 2004-present Sub-Investigator: Protocol C1538/3027/NA/MN: “A Phase 3, Randomized, Double-Blind, Placebo- Controlled, Parallel-Group Study to Assess the Efficacy and Safety of PROVIGIL (Modafinil) Treatment in Children and Adolescents With Excessive Sleepiness Associated With Narcolepsy “ Cephalon, Inc. March 2005 – present Sub-Investigator: Protocol C1538/3029/ED/MN: “ A One Year Open Label, Flexible-Dosage Extension Study to Assess the Safety and Continued Effectiveness of PROVIGIL (Modafinil) Treatment in Children and Adolescents with Excessive Sleepiness Associated With Narcolepsy of Obstructive Sleep Apnea/Hypopnea Syndrome”
March 2005 – present Sub-Investigator: Protocol 091-061: “A Multicenter, Double-Blind, Double-Dummy, Randomized, Active-Controlled, Parallel Group Long-Term Safety Study of 15 mcg and 25 mcg Arformoterol Tartrate Inhalation Solution BID in the Treatment of Subjects with Chronic Obstructive Pulmonary Disease”
Sub-Investigator: Protocol 101468/205: “A 12-Week, Placebo Controlled, Parallel Group Study to Assess the Efficacy and Safety of Ropinirole XR (Extended Release) in patients with Restless Legs Syndrome”
Sub-Investigator: Protocol 101468/206: “A 52 week Open Label Study to Assess the Long Term Safety of Ropinirole Extended Release (XR) In Patients with Restless Leg Syndrome”
Protocol H9U-MC-MDBD: “A randomized, double-blind comparison of 5 mg of LY2422347, 15 mg of LY 2422347, and PLACEBO In the treatment of patients with primary insomnia”
Protocol 091-00: “Multicenter, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Ezetimibe/Simvastatin and Niacin (Extended Release Tablet) Co-Administered in Patients with Type IIa or Type IIb Hyperlipidemia”
Protocol 201-069: “A 12-Week Double-Blind, Parallel-Group, Placebo-and Active-Controlled Trial to Evaluate the Efficacy and Safety of Formoterol Fumarate Inhalation Solution 20 mcg/0.5 mL delivered by OMRON MicroAir NE-U22V nebulizer in the Treatment of Patients with Chronic Obstructive Pulmonary Disease”
Protocol BY217.M2-125: “A 52 weeks, double-blind study with 500 mcg roflumilast once daily versus placebo”
Protocol PRX-CP-017: “A Randomized, Double-Blind, Placebo-Controlled Study to evaluate the Short-Term efficacy and safety of PRX-08066 in Patients with Pulmonary Hypertension Secondary to Chronic Obstructive Pulmonary Disease”Predix Pharmaceuticals Holdings, Inc. June 2006-present
Europe-Russia in the gas market. What kind of partnership does the future hold? Anne-Grete Ellingsen, 2010 Background The oil embargo in 1973 brought the energy policy on the agenda in The European Union for the first time. In 1974 it was agreed to diversify the energy sources and the supply to improve the security of supply. New attempts to create a common energy policy were made in 1
International Journal for Parasitology 29 (1999) 619±625The eect of chloroquine treatment on the infectivity ofInstitute of Cell, Animal and Population Biology, Division of Biological Sciences, University of Edinburgh, Edinburgh EH9 3JT, UKReceived 19 October 1998; received in revised form 3 December 1998; accepted 3 December 1998The antimalarial drug chloroquine has been reported to in